Radiofrequency catheter ablation in the treatment of Wolff-Parkinson- White syndrome

سال انتشار: 1383
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 34

فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_HMJ-8-1_019

تاریخ نمایه سازی: 29 بهمن 1402

چکیده مقاله:

Introduction: Tachyarrhythmias in Wolf Parkinson White (WPW) syndrome, can be a life threatening factor. Antiarrhythmic drug therapy in this syndrome, has not been completely acceptable. Efficacy, safety and economy of Radio Frequency Catheter Ablation (RFCA) in western studies, has made it as the treatment of choice. In the present study, efficacy of RFCA in the ablation of accessory pathway(s) and also, its complication and recurrence rate were studied in Modarres Hospital, Tehran, Iran. Methods: In this clinical trial study, ۶۳ patients with WPW syndrome and over ۱۶ years old were selected. Accessory pathway(s) in Electrophysiologic Study (EPS) laboratory was confirmed and ablation with radiofrequency energy was performed. If successful, the patients were followed up for one year. The results were analyzed with Mc Nemar’s method and p<۰.۰۵ was considered significant. Results: Out of sixty three patients, ۳۶ were male and ۲۷ were female with the mean age of ۳۸.۴±۱۴.۹ years. The most common accessory pathways were in left free wall (۵۲.۴%) and then in septal region (۳۱.۷%), right free wall (۹.۵%) and multiple accessory pathways (۶.۳%). The success rate in the ablation of accessory pathways, in general, was ۹۰.۵%. Maximum success was in septal pathways (۹۵%) and minimum in right accessory pathways (۸۳%) and in multiple accessory pathways (۷۵%). There was no meaningful relationship between efficacy of RFCA and age or sex. There was not any complication. The recurrence rate in a one year period was ۴.۸%. Conclusion: In this study, the result of RFCA in ablation of accessory pathway(s) and treatment of arrhythmia was comparable with previous western studies. So in our country, RFCA as the first therapy of choice in WPW syndrome is recommended.